B Cell-Specific Deletion of Protein-Tyrosine Phosphatase Shp1 Promotes B-1a Cell Development and Causes Systemic Autoimmunity  by Pao, Lily I. et al.
Immunity
ArticleB Cell-Specific Deletion of Protein-Tyrosine
Phosphatase Shp1 Promotes B-1a Cell
Development and Causes Systemic Autoimmunity
Lily I. Pao,1,* Kong-Peng Lam,2 Joel M. Henderson,3 Jeffery L. Kutok,3 Marat Alimzhanov,4 Lars Nitschke,5
Matthew L. Thomas,6,7 Benjamin G. Neel,1 and Klaus Rajewsky4,*
1 Cancer Biology Program, Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center,
Boston, MA 02115, USA
2 Laboratory of Molecular and Cellular Immunology, Biomedical Sciences Institutes, Agency for Science, Technology and Research
and Singapore Immunology Network, Proteos, Singapore 138673, Singapore
3 Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115, USA
4 The CBR Institute for Biomedical Research, Harvard Medical School, Boston, MA 02115, USA
5 Department of Genetics, University of Erlangen, 91058 Erlangen, Germany
6 Howard Hughes Medical Institute and Department of Pathology, Washington University School of Medicine, St. Louis,
MO 63110, USA
7 This author died during the early stages of this work.
*Correspondence: lpao@bidmc.harvard.edu (L.I.P.), rajewsky@cbr.med.harvard.edu (K.R.)
DOI 10.1016/j.immuni.2007.04.016SUMMARY
Spontaneous loss-of-function mutations in the
protein-tyrosine phosphatase Shp1 cause the
motheaten phenotype, characterized by wide-
spread inflammation and autoimmunity. Be-
cause Shp1 is expressed in all hematopoietic
cells, it has been unclear which aspects of the
motheaten phenotypes are primary effects of
Shp1 deficiency. We generated mice (Ptpn6f/f;
CD19-cre) that delete Shp1 specifically in B
cells. Analysis of these mice indicates that the
increase in B-1a cells in motheaten mice is
a cell-autonomous consequence of Shp1 defi-
ciency. Shp1-deficient B-1a cells could be
derived from adult bone marrow and had N-
nucleotide additions, consistent with an adult
origin. Shp1 deficiency altered calcium
response evoked by B cell antigen receptors
and impaired CD40-evoked proliferation.
Young Ptpn6f/f;CD19-cre mice exhibited ele-
vated serum immunoglobulins and impaired
antibody responses to immunization, whereas
older Ptpn6f/f;CD19-cre mice developed sys-
temic autoimmunity, characterized by DNA
antibodies and immune complex glomerulone-
phritis. Thus, Shp1 deficiency in B cells alone
perturbs B cell development and causes
autoimmune disease.
INTRODUCTION
B lymphoid progenitors undergo several differentiation
steps in the bone marrow (BM), including rearrangementof their immunoglobulin (Ig) loci, leading to expression of
B cell antigen receptors (BCRs) on their cell surface.
They then migrate to the spleen as BCR+ transitional B
cells, and in the spleen they mature into full-fledged follic-
ular ‘‘B-2’’ cells. Although B-2 cells predominate, other B
cell subsets, including marginal zone (MZ) B cells and
‘‘B-1’’ cells, also reside in the spleen. Although rare in
the spleen, B-1 cells comprise a substantial fraction of B
cells in the peritoneal and pleural cavities and are believed
to contribute primarily to T independent responses
(Berland and Wortis, 2002).
B-1 cell ontogeny remains controversial, with two gen-
eral models proposed. The ‘‘lineage model’’ holds that
B-1 and B-2 cells are derived from two developmentally
defined cell lineages, with persistent B-1a cells in adult
animals because of their ability to self-renew (Kantor and
Herzenberg, 1993). Support for this model is provided by
transplantation experiments in which fetal and neonatal
liver or omentum gives rise to CD5+ B-1 (B-1a) cells,
whereas adult BM yields B-2 cells. The recent identifica-
tion of lineage (Lin)B220CD19+AA4.1+ cells in adult
BM, which have a propensity to generate B-1 cells, lends
support to the idea that B-1 cells are derived from a distinct
cell lineage (Montecino-Rodriguez et al., 2006). The alter-
native ‘‘induced-differentiation’’ model proposes that
B-1a cells derive from B-2 cells exposed to strong BCR
signals (Berland and Wortis, 2002; Haughton et al.,
1993). Consistent with this model, BCR cross-linking in
the presence of appropriate stimuli (e.g., interleukin-6)
induces splenic B-2 cells to express CD5 and acquire
other B-1a cell features, including phorbol ester respon-
siveness and downregulation of CD23 and IgD (Berland
and Wortis, 2002). Studies of genetically manipulated
mice indicate that the strength of BCR signaling may con-
trol the development, persistence, or both of B-1a
and B-2 cells. Mutations that impair BCR signal strength
(e.g., Rho-family GTP-GDP exchange factor Vav orImmunity 27, 35–48, July 2007 ª2007 Elsevier Inc. 35
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B Cell-Autonomous Effects of Shp1 Deficiencyphospholipase PLCg2 deletion) result in reduced B-1a
and B-2 cells, whereas mutations that enhance BCR
signaling (e.g., CD22 or protein tyrosine kinase Lyn dele-
tion), expand the B-1a population (Berland and Wortis,
2002; Casola et al., 2004).
The mouse mutant, motheaten (me/me), and its allelic
variant, viable motheaten (mev/mev), carry mutations in
the genePtpn6, which encodes the protein-tyrosine phos-
phatase Shp1 (Shultz et al., 1993; Tsui et al., 1993).
Whereas me/me mice lack Shp1 protein, mev/mev mice
express aberrantly spliced Shp1 variants that retain
20% catalytic activity (Kozolowski et al., 1993). Shp1 is
expressed in hematopoietic cells and plays a signal-
attenuating role in pathways initiated by many growth
factors, cytokines, and immunoreceptor tyrosine-based
activation motif (ITAM)-containing receptors (Neel et al.,
2003). Consequently, me/me and mev/mev mice exhibit
multiple hematologic, inflammatory, and autoimmune
defects. The key phenotypic features, including retarded
growth, alopecia, and inflamed paws, manifest within
1–2 weeks after birth, and the mice die from interstitial
pneumonitis within 12 weeks of age. During their short
lives, these mice develop enlarged spleens and lymph
nodes, containing large numbers of myeloid cells, plasma
cells, and Mott cells. The myeloid cell infiltrates in the skin,
liver, muscles, and lung are likely to cause tissue damage
(Shultz, 1998). Although me/me mice have a shorter life
span thanmev/mev mice, their overall phenotype is similar;
hence, we hereafter refer generically to ‘‘motheaten mice’’
and the ‘‘motheaten phenotype,’’ respectively.
Although the development of inflammation and their
early demise do not require B and T cells, motheaten
mice have multiple lymphoid abnormalities, including hy-
pergammaglobulinaemia with circulating autoantibodies
and immune-complex deposition in the thymus, lungs,
and kidneys (Shultz, 1998). Although the absolute number
of splenic B cells is normal, motheaten mice have an
increased percentage of splenic B-1a cells, suggesting
that Shp1 deficiency causes expansion of B-1a cells at
the expense of B-2 cells. Consistent with the reduced
number of B-2 cells, BM B cell development is severely
impaired inmotheatenmice. Given the widespread inflam-
Figure 1. Generation of a Conditional Ptpn6 Allele
(A) Southern blot of SpeI-digested genomic DNA from two G418-resis-
tant (G418r) clones and wild-type ES cells, hybridized with the probe in
(Figure S1).
(B) Southern blot of SpeI-digested genomic DNA from wild-type ES
cells and two G418-sensitive (G418s) clones, hybridized with the
same probe.36 Immunity 27, 35–48, July 2007 ª2007 Elsevier Inc.mation and myeloid expansion in motheaten mice, it has
been difficult to define which lymphoid defects are cell
autonomous; indeed, early studies suggested that at least
some B cell abnormalities in these mice are caused by
aberrant myeloid cells (Hayashi et al., 1988; Medlock
et al., 1987). Whether B-1a cell expansion and autoimmu-
nity in motheaten mice are B cell-autonomous effects of
Shp1 deficiency remain unclear.
Cyster and Goodnow attempted to address these
issues by reconstituting mice with a mixture of wild-type
(WT) and motheaten BM. The resultant chimeras lacked
obvious inflammatory lesions (Cyster and Goodnow,
1995), and the motheaten-derived B cells in these chi-
meras had a B-2 phenotype, increased BCR-evoked cal-
cium flux, and a reduced signaling threshold for self-
antigen. Nevertheless, motheaten-derived myeloid cells
may have influenced B cell development in these chi-
meras even in the absence of overt inflammatory disease.
Also, because this study used Ig-transgenic mice that
dictate development of B-2 cells, the effect of Shp1 defi-
ciency on B-1 versus B-2 cell development remained
unclear. To define the B cell-autonomous effects of Shp1
deficiency unambiguously, we analyzed mice lacking
Shp1 expression only in B cells.
RESULTS
Generation of a Conditional Ptpn6 Allele
The murine Ptpn6 gene has two alternative first exons,
exon 1(I), expressed primarily in epithelial cells and 1(II),
found in hematopoietic cells (Martin et al., 1999). We gen-
erated a targeting vector (Figure S1 in the Supplemental
Data available online) to conditionally delete exons 1(II)–
9, electroporated ES cells, and identified homologous
recombinants by Southern blotting (Figure 1A). Two
such clones were transiently transfected with a Cre-
encoding plasmid to excise the loxP-flanked (floxed)
neomycin resistance cassette (neor). Two clones with an
appropriately floxed (f) locus were used to generate
chimeras (Figure 1B), which were bred to C57BL/6 mice
to obtain germline transmission of the floxed allele.
Mice homozygous for floxed Ptpn6 (Ptpn6f/f) were
normal, indicating that the inserted loxP sites did not per-
turb Shp1 expression. Ptpn6f/f mice were crossed to mice
that carried the Mx1-cre transgene, and that expressed
Cre recombinase widely, including in hematopoietic cells,
in response to type I interferon (IFN) (Ku¨hn et al., 1995).
Ptpn6f/f neonates with or without the Mx1-cre transgene
were injected with a single dose of IFNa. Only those with
the Mx1-cre transgene developed the motheaten pheno-
type (data not shown), confirming that deletion of Ptpn6
exons 1(II)–9 is sufficient to induce the motheaten pheno-
type and indicating that floxed Ptpn6 mice can be used to
dissect the cell-type-specific functions of Shp1.
Shp1 Deficiency in B Cells Promotes B-1a Cell
Differentiation
To assess the effects of Shp1 deficiency in B lympho-
cytes, we crossed Ptpn6f/f with CD19-cre mice (Rickert
Immunity
B Cell-Autonomous Effects of Shp1 Deficiencyet al., 1997). Splenic, peritoneal, and BM-derived macro-
phages from 4- to 8-month-old Ptpn6f/f;CD19-cre mice
showed no evidence of Shp1 deletion (Figure S2; data
not shown), consistent with studies of CD19-cre mice
crossed to floxed enhanced yellow fluorescent protein
(eYFP) reporter mice (Ye et al., 2003). Thus, CD19-cre
expression appears to promote floxed Ptpn6 excision
specifically in B cells.
Consistent with earlier reports that B cells are dispens-
able for the development of the inflammatory disease in
motheaten mice, Ptpn6f/f;CD19-cre mice exhibited no
overt abnormalities (Shultz, 1998). The absolute numbers
of splenocytes (Figure 2A) and splenic CD19+ B cells (Fig-
ures 2B and 2C) were similar in 11- to 12-week-old control
Ptpn6+/+;CD19-cre and mutant Ptpn6f/f;CD19-cre mice.
However, splenic B cells in mutant mice expressed ele-
vated amounts of CD19 (Figure 2D). Also, in sharp con-
trast to normal splenic B cells, most IgM+ splenic B cells
in mutant mice expressed low amounts of surface CD5
and B220, reminiscent of B-1a cells (Figures 2B and 2C).
Despite their reduced B220 expression, these splenic B
cells expressed large amounts of CD45, indicating switch-
ing of B220 to other isoforms (Figure 2D). Consistent with
the B-1a phenotype, surface IgD expression also was
decreased in Shp1-deficient splenic B cells in mutant
mice. However, unlike the IgMhi phenotype associated
with normal B-1a cells, surface IgM was reduced in Shp1-
deficient splenic B cells (Figure 2D). CD43 is normally
expressed by a fraction of IgM+CD5+ splenic B-1a cells
(Figure S3A), and the percentage and absolute number
of CD43+IgM+CD5+ cells were increased in the spleens
of mutant mice (Figure S3B). There was also a substantial
expansion of CD43+ cells within the splenic IgM+CD5
population (Figures S3A and S3B). These CD43+IgM+-
CD5 cells may represent B-1b cells, suggesting that
Shp1 deficiency affects this population as well.
Closer examination of the splenic B cell subsets in
Ptpn6f/f;CD19-cre mice revealed a clear reduction in
CD23+CD21+IgM+ follicular (FO) B cells and CD21hiIgMhi-
CD1dhi MZ B cells because the majority of IgM+ B cells
were CD23 and CD21 (Figures 2E and 2G, data not
shown). Although AA4.1+B220hi transitional (Tr) B cells
were present, they too were reduced in Ptpn6f/f;CD19-
cre spleens (Figures 2F and 2G). Within the Tr B com-
partment, the proportions of the T1 (IgM+CD23), T2
(IgM+CD23+), and T3 (IgMloCD23+) subsets were
decreased, with most AA4.1+B220hi B cells being
IgMloCD23. Thus, deletion of Ptpn6 in developing B cells
has a profound effect on B cell differentiation, resulting in
splenic B cells that predominantly express surface
markers characteristic of B-1a cells (Hardy and Haya-
kawa, 2001).
We asked whether the persistent B-2 cells in the
spleens of Ptpn6f/f;CD19-cre mice had failed to delete
Shp1. IgM+ B cells from control (Ptpn6f/+;CD19-cre or
Ptpn6f/f) or mutant mice were collected by FACS on the
basis of their CD5 expression and analyzed by Southern
blotting and immunoblotting. Ptpn6-gene deletion was ef-
ficient in both the CD5+ and CD5 populations (Figure 2H),but some Shp1 protein was detectable in the CD5 frac-
tion (Figure 2I). This correlation between CD5 expression
and the absence of Shp1 protein suggests that developing
B cells in Ptpn6f/f;CD19-cre mice may acquire the B-1a
phenotype as their Shp1-protein amounts decrease.
As in the spleen, the percentage of IgM+ B cells that
were CD5+ and B220lo was increased in the lymph nodes
of Ptpn6f/f;CD19-cre mice (Figures 3A and 3B). Interest-
ingly, the number of CD19+ B cells was significantly re-
duced, reflecting a 4-fold decrease in IgM+CD5 B-2 cells,
concomitant with a 3-fold increase in IgM+CD5+ B cells
(Figure 3B, p < 0.0005). By contrast, Shp1 deficiency in
B cells significantly increased the total number of perito-
neal cells (Figure 2A, p < 0.05) because of a 5-fold increase
in CD19+ B cells (Figures 3C and 3D). Approximately 90%
of IgM+ peritoneal B cells were CD5+ and B220lo. The dis-
tinct effects of Shp1 deficiency on B cell numbers at var-
ious anatomical locations presumably reflect the relative
ability of wild-type and Shp1-deficient B cells to home,
survive, or expand in different sites.
Typically, B-1a cells are absent in normal BM. However,
we readily detected IgM+CD5+ B cells in BM from Ptpn6f/f;
CD19-cre mice (Figures 3E and 3F). The BM B220hiIgM+
(fraction F) was significant reduced, whereas other frac-
tions remained normal (Figure S4). Because CD19-cre
mediated excision is incomplete in BM B lymphoid pre-
cursors, it remains unclear whether the IgM+CD5+ B cells
in the BM of Ptpn6f/f;CD19-cre mice are recirculating,
mature B cells or newly generated B cells that acquire
the B-1a phenotype as their Shp1-protein amounts
decline.
Adult Origin of B-1a Cells in Ptpn6f/f;CD19-cre Mice
To investigate the origin of B-1a cells in Ptpn6f/f;CD19-
cre mice, we transferred BM cells from adult Ly5.2+
Ptpn6f/f;CD19-cre mice into irradiated Ly5.1+ hosts.
Prior to transfer, the BM was depleted of Ter119+,
IgM+, and CD5+ cells. For a control, we also transferred
BM cells from adult Ly5.2+ Ptpn6+/+;CD19-cre mice af-
ter similar depletion into another cohort of irradiated
Ly5.1+ hosts. Less than 2% of the cells were Ig+ in
the immuno-depleted BM (Figures 4A and 4B). The re-
sulting chimeras had donor (Ly5.2+) IgM+ B and CD5+
T cells (Figure 4C) in their spleens (upper panels), lymph
nodes (middle panels), and peritoneum (lower panels).
Although fewer Ptpn6f/f;CD19-cre-derived IgM+ cells
than Ptpn6+/+;CD19-cre-derived IgM+ cells were found
in the spleen, the opposite was observed in the perito-
neum (Figure 4D). Furthermore, the percentages of
donor-derived IgM+CD5+ cells in the spleen and perito-
neum of Ptpn6f/f;CD19-cre chimeras were greater than
those found in Ptpn6+/+;CD19-cre chimeras
(Figure 4E). We also sequenced the VHJ558D and DJH1
junctions in splenic CD5+ and CD5 B cells isolated
from 6-month-old Ptpn6f/f;CD19-cre mice and found
that these B cells contained N nucleotide additions (Ta-
ble S1). Taken together, these findings strongly suggest
an adult origin for the B-1a cells in Ptpn6f/f;CD19-cre
mice.Immunity 27, 35–48, July 2007 ª2007 Elsevier Inc. 37
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(A) Total spleen (SPL), peripheral lymph node (LN), peritoneal exudate (PC), and BM cells recovered from 11- to 12-week-oldPtpn6+/+;CD19-cre (filled
bars) and Ptpn6f/f;CD19-cre (open bars) mice (n = 4 each), plotted as mean ± SEM. *p < 0.05, paired two-tailed t test.
(B) Ptpn6+/+;CD19-cre (left) and Ptpn6f/f;CD19-cre (right) splenocytes, stained for expression of the indicated markers. Numbers represent percent-
ages of cells within the lymphocyte gate, representative of at least six experiments.
(C) Absolute numbers of CD19+, IgM+CD5, and IgM+CD5+ splenocytes from Ptpn6+/+;CD19-cre (filled bars) and Ptpn6f/f;CD19-cre (open bars) mice
(n = 4 each), plotted as mean ± SEM. **p < 0.005 by paired two-tailed t test.
(D) Histograms of CD19, CD45, IgM, and IgD levels on CD19+ splenic B cells from Ptpn6+/+;CD19-cre (red) and Ptpn6f/f;CD19-cre (blue) mice. Data
represent at least five experiments.38 Immunity 27, 35–48, July 2007 ª2007 Elsevier Inc.
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B Cell-Autonomous Effects of Shp1 DeficiencyFigure 3. Effects of BCell-SpecificPtpn6
Deletion on Other Lymphoid Populations
(A) Flow cytometry of lymph node (LN) cells
from 11- to 12-week-old Ptpn6+/+;CD19-cre
(left) and Ptpn6f/f;CD19-cre (right) mice,
stained for surface IgM, CD5, and B220. Num-
bers represent percentages of cells within the
lymphocyte gate, representing at least four
experiments.
(B) Absolute numbers of LN CD19+, IgM+CD5
and IgM+CD5+ B cells from Ptpn6+/+;CD19-cre
(filled bars) and Ptpn6f/f;CD19-cre (open bars)
mice (n = 4 each), plotted as mean ± SEM. *p <
0.05; **p < 0.005; ***p < 0.0005 by paired two-
tailed t test.
(C) Peritoneal (PC) cells from 11- to 12-week-
old Ptpn6+/+;CD19-cre (left) and Ptpn6f/f;
CD19-cre (right) mice, stained for surface
IgM, CD5, and B220. Numbers represent per-
centages of cells within the lymphocyte gate;
representative of at least ten experiments.
(D) Absolute numbers of PC CD19+,
IgM+CD5, and IgM+CD5+ B cells from
Ptpn6+/+;CD19-cre (filled bars) and Ptpn6f/f;
CD19-cre (open bars) mice (n = 4 each), plotted
as mean ± SEM. *p < 0.05 by paired two-tailed
t test.
(E) BM cells from 11- to 12-week-old Ptpn6+/+;
CD19-cre (left) and Ptpn6f/f;CD19-cre (right)
mice stained for surface IgM, CD5, and B220,
representing at least six experiments.
(F) Absolute numbers of BM CD19+, IgM+CD5
and IgM+CD5+ B cells from Ptpn6+/+;CD19-cre
(filled bars) and Ptpn6f/f;CD19-cre (open bars)
mice (n = 4 each), plotted as mean ± SEM. *p <
0.05; **p < 0.005 by paired two-tailed t test.Altered Antibody Responses in Ptpn6f/f;CD19-cre
Mice
Similar to motheaten mice (Shultz, 1998), younger (8- to
15-week-old) Ptpn6f/f;CD19-cre mice had increased se-
rum IgM, IgG2a, and IgG3, whereas IgA, IgG1, and IgG2b
concentrations were not altered significantly (Figure 5A).
However, unlike motheaten mice (Sidman et al., 1986),Ptpn6f/f;CD19-cre mice did not show augmented usage
of l light chains in serum antibodies or surface Ig (data
not shown).
To determine the ability of Ptpn6f/f;CD19-cre mice to
mount specific antibody responses, groups of 8-week-
old mice were immunized with either a thymus-dependent
(TD; NP18-CG) or a thymus-independent type II (TI-II;(E) Representative analysis of splenocytes stained with CD19, IgM, CD21, and CD23 antibodies. Numbers indicate percentages of cells within the
CD19+ gate.
(F) Representative analysis of splenocytes stained with CD19, IgM, AA4.1, B220, and CD23 antibodies. Numbers indicate percentages of cells within
the CD19+ gate (upper) or CD19+B220+AA4.1+ gate (lower).
(G) Quantification of splenic B cell subsets as shown in (E) and (F) from Ptpn6+/+;CD19-cre (filled bars) and Ptpn6f/f;CD19-cre (open bars) mice (n = 4
each), plotted as mean ± SEM. *p < 0.05; **p < 0.005, paired two-tailed t test.
(H) Southern blot, showing deletion efficiency in IgM+CD5 and IgM+CD5+ splenic B cells from the indicated mice. DNA from Ptpn6f/+;Mx1-cre sple-
nocytes with incomplete deletion of the Shp1 locus was resolved on the same gel (right-most lane), to indicate floxed, deleted, and wild-type alleles,
respectively.
(I) Shp1-protein amounts in Ptpn6f/f;CD19-cre splenic B cells. The indicated numbers of IgM+CD5+ and IgM+CD5 cells were lysed, immunoblotted
for Shp1, and reprobed for Grb2 to control for loading.Immunity 27, 35–48, July 2007 ª2007 Elsevier Inc. 39
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Mice with B Cell-Specific Ptpn6 Deletion
(A) BM predepletion (upper panels) and post-
depletion (lower panels) of IgM+, CD5+, and
Ter119+ cells from 11- to 12-week-old Ly5.2+
Ptpn6+/+;CD19-cre (left) and Ptpn6f/f;CD19-
cre (right) mice, stained for IgM and CD5. Num-
bers represent percentages of cells within the
total live cell gate; data are representative of
three experiments.
(B) Flow cytometry of BM prepared as shown in
(A), stained for Igk.
(C) Splenocytes (SPL), LN cells, and peritoneal
exudates (PC) from Ly5.1+ mice 8 weeks after
reconstitution with IgM+-, CD5+-, and
Ter119+-depleted BM from 11- to 12-week-
old Ly5.2+ Ptpn6+/+;CD19-cre (left) and
Ptpn6f/f;CD19-cre (right) mice, stained for IgM
and CD5. Numbers indicate percentages of
cells within the Ly5.2+ lymphocyte gate. In
the Ptpn6+/+;CD19-cre chimera shown,
Ly5.2+ cells were 50%, 54%, and 50% of total
lymphocytes recovered from spleen, LN, and
peritoneum, respectively. For the Ptpn6f/f;
CD19-cre chimera, Ly5.2+ cells were 84%,
83%, and 93% of total lymphocytes recovered
from the same sites, respectively.
(D) Quantification of Ly5.2+ donor-derived
IgM+ cells in (C) from Ptpn6+/+;CD19-cre (filled
circles, n = 4) and Ptpn6f/f;CD19-cre (open cir-
cles, n = 5) mice. Each symbol represents an
individual chimera, with the bar indicating the
mean percentage. *p < 0.05 by unpaired two-
tailed t test.
(E) Quantification of Ly5.2+ donor-derived
IgM+CD5+ and IgM+CD5 cells in (C) from
Ptpn6+/+;CD19-cre (filled circles, n = 4) and
Ptpn6f/f;CD19-cre (open circles, n = 5) mice.
Each symbol represents an individual chimera.
The bar indicates the mean percentage. *p <
0.005; **p < 0.0005; ***p < 0.0001 by unpaired
two-tailed t test.NP25-Ficoll) antigen. Even prior to immunization (day 0),
sera from Ptpn6f/f;CD19-cre mice contained elevated
amounts of k bearing Ig and IgM that cross-reacted with
NP-BSA (Figures 5B and 5C). Mutant mice responded to
NP-CG, as shown by an increase of NP-binding IgM and
IgG1 as well as total k or l light-chain-bearing antibodies
in their sera on days 7, 14, and 21 after immunization,
but the magnitude of the increase was lower than that in
control mice (Figure 5B). The response of Ptpn6f/f;CD19-
cre mice to NP-Ficoll immunization was severely impaired
(Figure 5C). No NP-specific IgM or IgG1 response could
be detected in immunized mutant mice, and the IgG3
response was drastically reduced compared to controls
(Figure 5C), indicating a compromised ability of Shp1-
deficient B cells to react against TD and TI-II antigens.40 Immunity 27, 35–48, July 2007 ª2007 Elsevier Inc.BCell-Specific-Shp1 Deficiency Affects Proliferation
and Calcium Mobilization
To investigate why Ptpn6f/f;CD19-cre mice cannot mount
an effective antigen response, we assessed the ability of
purified CD19+ B cells (which include B-1 and B-2 cells)
from control Ptpn6f/+;CD19-cre and Ptpn6f/f;CD19-cre
spleens to respond to various stimuli. Compared to con-
trols, Ptpn6f/f;CD19-cre B cells proliferated substantially
less upon stimulation by anti-IgM or anti-CD40, as well
as by combinations of anti-IgM with anti-CD40 or IL-4.
LPS-evoked proliferation was similar in control and
Shp1-deficient splenic B cells, indicating that Shp1-defi-
cient B cells are not intrinsically unable to proliferate in
culture and that Toll-like receptor 4 signaling is normal
(Figure 6A).
Immunity
B Cell-Autonomous Effects of Shp1 DeficiencyFigure 5. Altered B Cell Function in Serum Ig Production and Humoral Responses
(A) Antibody titers from 8-week-old control (filled circles, n = 16) and Ptpn6f/f;CD19-cre (open circles, n = 12) mice. Controls include Ptpn6f/f, Ptpn6f/+,
Ptpn6f/+;CD19-cre, and Ptpn6+/+;CD19-cre mice. Each symbol represents an individual mouse. The bar indicates the mean titer. *p < 0.05; ***p <
0.0005 by Wilcoxon one-tailed t test.
(B) T cell-dependent immune response. Groups of eight control and six Ptpn6f/f;CD19-cre mice were immunized with 50 mg NP18-CG in alum and bled
before (day 0) and on days 7, 14, and 21 postimmunization. NP-specific titers were determined by ELISA and plotted as the geometric mean ± 95%
confidence intervals (CI). Filled circles represent control mice; open circles represent Ptpn6f/f;CD19-cre mice. Points on the x axis are below the
detection limit. *p < 0.05; **p < 0.005; ***p < 0.0005 by unpaired one-tailed t test.
(C) T cell-independent immune response. Ptpn6+/+;CD19-cre and Ptpn6f/f;CD19-cre mice (n = 4 each) were immunized with 20 mg of NP25-Ficoll in
PBS, and NP-specific titers on days 0, 7, 14, and 21 were determined by ELISA. Data are plotted as the geometric mean ± 95% CI. Filled circles
represent Ptpn6+/+;CD19-cre mice; open circles represent Ptpn6f/f;CD19-cre mice. For IgG1, points on the x axis are below the detection limit.
*p < 0.05; **p < 0.005; ***p < 0.0005 by unpaired one-tailed t test.Immunity 27, 35–48, July 2007 ª2007 Elsevier Inc. 41
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B Cell-Autonomous Effects of Shp1 DeficiencyFigure 6. B Cell Responses in Ptpn6f/f;CD19-cre Mice
(A) Ex vivo proliferation of splenic B cells. CD19+ B cells from 9- to 10-week-old Ptpn6f/+;CD19-cre and Ptpn6f/f;CD19-cre mice were cultured with
LPS (10 mg/ml), IgM antibody (5 or 10 mg/ml, F(ab’)2), CD40 antibody (0.75 mg/ml), IL-4 (25 U/ml), or IgM antibody (5 mg/ml, F(ab’)2) together with either
CD40 antibody (0.75 mg/ml) or IL-4 (25 U/ml), and [3H] thymidine incorporation was assessed. One of two experiments with similar results is shown.
Data are expressed as mean ± SEM. *p < 0.05; **p < 0.005; ***p < 0.0005 by paired two-tailed t test.
(B) Ex vivo proliferation of peritoneal B-1a cells. Histograms show CFSE intensities of peritoneal CD5+CD19+ B cells from 10- to 11-week-oldPtpn6+/+;
CD19-cremice (left) andPtpn6f/f;CD19-cremice (right) 3 days after culture, unless otherwise indicated. Cells were either left unstimulated (gray line) or
were stimulated (black line) with 10 mg/ml IgM antibody (F(ab’)2, top), 2.5 mg/ml CD40 antibody (middle two), or 0.3 mg/ml PMA (bottom). One of two
experiments with similar results is shown.
(C) Calcium response in splenic B cells. Splenocytes were stimulated with IgM antibody (F(ab’)2, 1, 2, 5, or 10 mg/ml) at the indicated time (arrow) for
8 min. Intracellular calcium concentrations of splenic CD5+B220lo B-1a cells (middle panels) and splenic CD5-B220+ B-2 cells (right panels) from 11- to42 Immunity 27, 35–48, July 2007 ª2007 Elsevier Inc.
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IgM and, in contrast to B-2 cells, proliferate upon treat-
ment with phorbol esters (Berland and Wortis, 2002).
Hence, the apparent impairment of the anti-IgM-evoked
proliferative response in splenic B cells from Ptpn6f/f;
CD19-cre mice could reflect their predominantly B-1a
phenotype, rather than an intrinsic difference in BCR sig-
naling in Shp1-deficient cells. Indeed, like normal B-1a
cells, Shp1-deficient peritoneal B-1a cells proliferated in
response to PMA and failed to respond to anti-IgM stimu-
lation (Figure 6B). However, unlike normal B-1a cells,
which responded to anti-CD40 stimulation, the anti-
CD40-evoked response of Shp1-deficient peritoneal
B-1a cells was greatly reduced (Figure 6B).
We also assessed the ability of splenic B cells in
Ptpn6f/f;CD19-cre mice to mobilize calcium upon IgM
cross-linking. Because of the intrinsic signaling differ-
ences between B-1 and B-2 cells (Berland and Wortis,
2002), we examined CD5+ and CD5 B cells separately.
Upon anti-IgM stimulation, splenic CD5+B220lo B-1a cells
from Ptpn6f/f;CD19-cre mice exhibited a greater increase
in intracellular calcium concentration than their counter-
parts from Ptpn6+/+;CD19-cre mice (Figure 6C). In con-
trast, splenic CD5B220+ B-2 cells from Ptpn6+/+;CD19-
cre and Ptpn6f/f;CD19-cre mice exhibited comparable
IgM-mediated calcium responses (Figure 6C); the incom-
plete ablation of Shp1 protein in these cells (Figure 2I)
could contribute to this finding. Similar to splenic B-1a
cells, peritoneal CD5+B220lo B-1a cells from Ptpn6f/f;
CD19-cre mice also exhibited an increased response as
compared to peritoneal B-1a cells from Ptpn6+/+;CD19-
cre mice, but this enhancement was very modest and
detectable only at lower doses of stimulation (Figure 6D).
Unexpectedly, peritoneal CD5B220+ B-2 cells from
Ptpn6f/f;CD19-cre mice exhibited a decreased response
compared to such cells from Ptpn6+/+;CD19-cre mice,
suggesting that Shp1 may positively regulate BCR signal-
ing in B-2 cells under certain circumstances (Figure 6D).
Old Ptpn6f/f;CD19-cre Mice Develop Autoimmunity
Compared to age-matched controls, older (5–6 month)
Ptpn6f/f;CD19-cre mice had increased serum titers of
IgM, IgG2a, and IgG1 antibodies reactive to single
stranded (ss) DNA (Figure 7A). Ptpn6f/f;CD19-cre mice
also had elevated titers of IgM and IgG2a against double
stranded (ds) DNA (Figure 7B). Both k and l light chains
were associated with these autoantibodies against DNA
(Figures 7A and 7B).
Autopsies of 7- to 11-month-old Ptpn6f/f;CD19-cre
mice revealed multiple abnormalities, including enlarged
spleens and lymph nodes (Figure S5). Flow-cytometric
analysis of cells from these organs revealed increased
numbers of B and T lymphocytes, macrophages, and
granulocytes (data not shown). This is distinct from themotheaten mice’s hypercellularity, which mainly reflects
extramedullary hematopoiesis (Shultz, 1998). Hematoxy-
lin and eosin (H and E) staining of spleen and lymph-
node sections revealed increased numbers of plasma
and Mott cells (data not shown). Predominantly lympho-
cytic infiltrates also were seen in liver and lungs (Figures
7Cb and 7Cd) and, accordingly, immunostaining revealed
large numbers of B220+ B cells and CD3+ T cells in the
lung (Figures 7Db and 7Dd) and B220
+ infiltrates in the liver
(Figure 7Df). These findings differ from the motheaten
phenotype, which features myeloid infiltrates in these
tissues (Shultz, 1998). Increased B220+ cells also were
found in the thymic cortex (Figure 7Dh), in contrast to the
early thymic atrophy seen in motheaten mice (Shultz,
1998). Renal sections revealed glomerulonephritis (Fig-
ure 7Cf), and electron microscopy showed mesangial de-
posits of fine, granular, electron-dense material (Figure 7E,
asterisks), which stained positive for IgM (Figure 7E, lower
panel), consistent with immune-complex deposition.
Thus, deletion of Ptpn6 only in B cells eventually leads
to the development of an autoimmune disease with fea-
tures similar to systemic lupus erythematosus (SLE).
DISCUSSION
The complexity of the motheaten phenotype has hindered
efforts to define the primary effects of Shp1 deficiency in B
cells. By analyzing mice with B cell-specific Ptpn6 dele-
tion, we have identified B cell-autonomous and nonauton-
omous effects of Shp1. The dramatic increase in B-1a
cells at the expense of B-2 cells in Ptpn6f/f;CD19-cre
mice indicates that Shp1 deficiency affects this pheno-
type in a cell-autonomous fashion. Unlike motheaten
mice, however, Ptpn6f/f;CD19-cre mice do not have
increased serum IgG1, IgG2b, and IgA titers (Sidman
et al., 1986). Although the mechanism for the increase in
serum IgG2a in motheaten and Ptpn6
f/f;CD19-cre mice is
unclear, elevated IgM and IgG3 could be due to the
increase in B-1a cells, which normally produce these iso-
types (Berland and Wortis, 2002). Because isotype
switching requires T cells, Shp1 deficiency in T and
antigen-presenting cells may contribute to the enhanced
serum IgG and IgA titers in motheaten mice. The reported
hyperproliferative response of motheaten splenic B cells
to anti-Ig stimulation (Pani et al., 1995) also is not B cell
autonomous. Instead, B cell-specific Shp1 deficiency
actually reduces anti-IgM-induced splenic B cell prolifera-
tion, probably reflecting the great percentage of B-1a cells
in Ptpn6f/f;CD19-cre mice and the intrinsically different
responses of B-1a and B-2 cells to anti-IgM stimulation
(Berland and Wortis, 2002). Previous studies ofmotheaten
B cells did not assess CD40-mediated proliferation. Unex-
pectedly, we find that such responses are diminished in
peritoneal Ptpn6f/f;CD19-cre B-1a cells, by a mechanism12-week-old Ptpn6+/+;CD19-cre (red) and Ptpn6f/f;CD19-cre (blue) mice are presented as the ratio of bound to unbound Indo-1. B-1a and B-2 gates
were drawn as indicated in the dot plots (left).
(D) Calcium response in peritoneal B cells. PC cells were stimulated with IgM antibodies and their calcium responses assessed as in (C). Anti-B220 and
anti-CD5 pretreatment had no effect on calcium flux (data not shown). Data shown are representative of three independent experiments.Immunity 27, 35–48, July 2007 ª2007 Elsevier Inc. 43
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B Cell-Autonomous Effects of Shp1 DeficiencyFigure 7. Autoimmunity in Ptpn6f/f;CD19-cre Mice
(A) ssDNA antibody titers in sera of 5- to 7-month-old control (filled circles, n = 6) and Ptpn6f/f;CD19-cre (open circles, n = 6) mice. Each symbol
represents one animal. Titers below the detection limit are plotted on the x axis. *p < 0.05; **p < 0.005; ***p < 0.0001, unpaired one-tailed t test.
(B) dsDNA antibodies in the sera of 5- to 7-month-old control (filled circles, n = 6) and Ptpn6f/f;CD19-cre (open circles, n = 6) mice. *p < 0.05; **p <
0.005; ***p < 0.0005, unpaired one-tailed t test.
(C) H and E stained sections of liver (Ca and Cb), lungs (Cc and Cd), and kidney (Ce and Cf) from 8-month-old Ptpn6
f/+ (Ca, Cc, and Ce) and Ptpn6
f/f;
CD19-cre (Cb, Cd, and Cf) mice. Black arrows indicate cellular infiltrates. Liver and kidney sections are shown at 2003; lung sections are at 1003.
Data represent six mice (7 to 11 month old) of each genotype.
(D) IHC (2003) of lungs (Da–Dd), liver (De and Df) and thymus (Dg and Dh) from 7-month-old Ptpn6
f/+ (Da, Dc, De, and Dg) and Ptpn6
f/f;CD19-cre (Db, Dd,
Df, and Dh) mice, stained with B220 (Da, Db, and De–Dh) or CD3 antibodies (Dc and Dd). Reactive cells are red/brown (yellow arrows). Data represent
one of two mice of each genotype with similar results.44 Immunity 27, 35–48, July 2007 ª2007 Elsevier Inc.
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showed impaired antibody responses to antigenic chal-
lenges. To our knowledge, no such studies with the
motheaten mice have been reported. Although B-1 cells
are involved in T1-II responses (reviewed in Berland and
Wortis [2002]), they do not respond to NP-Ficoll, as used
in this study (Fo¨rster and Rajewsky, 1987). Instead, MZ
B cells appear to respond to this antigen (Guinamard
et al., 2000), so the impaired NP-Ficoll response in
Ptpn6f/f;CD19-cre mice could reflect their reduced MZ
population. How Shp1 deficiency in B cells affects the
TD response is not clear. The responding population
(B-2 cells) is reduced in Ptpn6f/f;CD19-cre mice and
shows incomplete Ptpn6 deletion. Thus, the impaired TD
response in Ptpn6f/f;CD19-cre mice may reflect a reduced
number of responding cells, rather than impaired respon-
siveness due to Shp1 deficiency. Whether Shp1-deficient
B-1a cells in Ptpn6f/f;CD19-cre mice also contribute to TD
response remains unknown. Finally, Ptpn6f/f;CD19-cre
mice develop systemic autoimmunity, characterized by
polyreactive autoantibodies, tissue infiltration with lym-
phoid cells, and immune-complex glomerulonephritis,
suggesting that Shp1-deficiency in B cells alone is suffi-
cient to elicit this pathology. Whereas the disease occurs
in Ptpn6f/f;CD19-cre mice only at >5 months of age, mo-
theaten mice exhibit such abnormalities within 3 weeks
of birth. Thus, absence of Shp1 in other cell types clearly
contributes to the full autoimmune phenotype in mo-
theaten mice.
Cell-transfer studies demonstrate the propensity of fetal
precursors to generate B-1a cells (Herzenberg et al.,
1986), although adult BM progenitors can generate B-1a
cells at low frequency (Berland and Wortis, 2002). The
identification of LinB220CD19+AA4.1+ B-1 cell precur-
sors in adult BM suggests that B-1a cells are not exclu-
sively fetal liver derived (Montecino-Rodriguez et al.,
2006). We found that recipients of adult Ptpn6f/f;CD19-
cre BM have abundant donor-derived B-1a cells. Thus,
Shp1-deficient B-1a cells, like wild-type B-1a cells, can
be generated from progenitors found in adult BM, a con-
tention supported by the similar extent of N nucleotide
addition in wild-type (Gu et al., 1990; Gu et al., 1992)
and Shp1-deficient B-1a cells from mice of similar age.
Preliminary experiments indicate that adult Ptpn6f/f;
CD19-cre mice have a normal number of LinB220C-
D19+AA4.1+ BM B-1 progenitors (data not shown), which
suggest that Shp1 deficiency may lead to expansion of B-
1a cells as they develop. However, the increased number
of splenic B-1a cells in Ptpn6f/f;CD19-cre mice occurs at
the expense of B-2 cells. Splenic B-1a and residual B-2
cells found in Ptpn6f/f;CD19-cre mice have different ex-
tents of Shp1 deletion, with low amounts of Shp1 protein
still detectable in B-2 cells. Conceivably as Shp1-protein
amounts decline in developing B-2 cells in Ptpn6f/f;
CD19-cre mice (i.e., after CD19-cre-mediated excisionof the floxed Ptpn6 allele), cells initially destined to be-
come B2 cells may be redirected into the B-1a pathway.
Alternatively, Shp1 deficiency could selectively promote
survival or expansion of B-1a cells while causing the death
of B-2 cells.
Numerous studies identify BCR signal strength as a crit-
ical determinant of B-1a cell development or mainte-
nance. Although both motheaten and Ptpn6f/f;CD19-cre
mice have increased number of B-1a cells, BM from
motheaten mice expressing an Ig transgene recognizing
hen-egg lysozyme (HEL) gives rise to splenic B cells with
a B-2 phenotype (Cyster and Goodnow, 1995). In the pres-
ence of soluble HEL, these motheaten-derived IgHEL B
cells are deleted rather than anergized, suggesting that
Shp1 deficiency does increase signaling strength.
Likewise, we find that Shp1 negatively regulates BCR-
evoked calcium response in splenic and peritoneal CD5+
B-1a cells, albeit to a different extent. Unexpectedly,
whereas splenic CD5 B-2 cells from Ptpn6f/f;CD19-cre
mice responded normally to anti-IgM, their peritoneal
counterparts had a reduced response. These findings
are difficult to interpret, because the compositions of
CD5 B cell compartment (e.g., B-1b, Tr, FO, and MZ) in
Ptpn6+/+;CD19-cre mice differ from those in Ptpn6f/f;
CD19-cre mice, and the analysis is further complicated
by incomplete Shp1 depletion in this fraction. Shp1 defi-
ciency in B-2 cells also may enhance BCR-mediated
calcium flux. Motheaten-derived IgHEL splenic B cells,
which are B-2 in phenotype, reportedly have enhanced
BCR-evoked calcium flux compared to their wild-type
counterparts (Cyster and Goodnow, 1995). However, the
possibility that the elevated response in motheaten-
derived IgHEL B cells reflects non-cell-autonomous effects
of Shp1 deficiency cannot be excluded.
Although Shp1 may directly associate with the BCR
(Pani et al., 1995), the signal-attenuating effects of Shp1
are believed to be mediated primarily via its binding to
inhibitory receptors (Neel et al., 2003). B cells express sev-
eral such receptors, including CD72, CD22, and paired
Ig-like receptor (PIR)-B (Pritchard and Smith, 2003); in
addition, B-1a cells express the inhibitory receptor CD5
(Berland and Wortis, 2002). The phenotypes of mice lack-
ing these inhibitory receptors reveal both similarities to
and differences from the effects of B cell-specific Shp1
deficiency in B-1a cell development, IgM-induced calcium
flux, and proliferative responses (Bikah et al., 1996; Lajau-
nias et al., 2002; Nitschke et al., 1997; O’Keefe et al., 1996;
Otipoby et al., 1996; Pan et al., 1999; Sato et al., 1996a;
Ujike et al., 2002). Indeed, Shp1 is likely to regulate differ-
ent aspects of B cell biology via combinations of several
different inhibitory receptors.
Ptpn6 deletion only in B cells causes autoantibody
production and systemic autoimmunity. Autoimmunity
was also reported in one line of mice lacking CD22
(O’Keefe et al., 1999), mice with FcgRII deficiency in B(E) Electron micrographs (upper panels) of glomerular segments from 8-month-old Ptpn6+/+;CD19-cre (left) and Ptpn6f/f;CD19-cre (right) mice. Me-
sangial thickenings and deposits are indicated with asterisks. Scale bars represent 5 mm. Lower panels show immunofluorescence of glomerular seg-
ments from Ptpn6+/+;CD19-cre (left panel) and Ptpn6f/f;CD19-cre (right panel) mice, demonstrating the presence of IgM in mesangial deposits.Immunity 27, 35–48, July 2007 ª2007 Elsevier Inc. 45
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B Cell-Autonomous Effects of Shp1 Deficiencycells (Bolland and Ravetch, 2000), and mice overexpress-
ing CD19 (Sato et al., 1996b). These findings, and our own,
suggest that defects solely in B lymphoid lineage cells
can break tolerance.
For Shp1, this conclusion hinges on the B lymphoid
specificity of the CD19-cre transgene. Studies of CD19-
cre mice involving a floxed eYFP reporter support the
B cell specificity of CD19-cre and argue against CD19-
cre-mediated excision in macrophages or other myeloid
cells (Ye et al., 2003). However, others report CD19 ex-
pression in non-B cells, including c-Kit+ peritoneal mast
cells (Gommerman et al., 2000) and a minor population
of CD11c+ splenic dendritic cells (DCs) (Munn et al.,
2004). We failed to detect any evidence (by PCR) of
Shp1 deletion in BM-derived mast cells from Ptpn6f/
f;CD19-cre mice (data not shown). Furthermore, although
we did detect a CD19+CD11chi splenocyte population,
these cells were IgM+, thereby strongly suggesting a B
cell origin (data not shown). Although we cannot formally
exclude the possibility that bona fide CD19+ mast cells
or DCs exist, we believe that the reported CD19+ ‘‘mast
cells’’ and ‘‘DCs’’ represent rare B cells that express
c-Kit and CD11c, respectively, and such cells could con-
tribute to autoimmunity in older Ptpn6f/f;CD19-cre mice.
We also cannot exclude the possibility that the hybrid
1293 C57BL/6 background of Ptpn6f/f;CD19-cre mice in-
fluences the pathogenesis and progression of the disease
(Bygrave et al., 2004). Nevertheless, because we failed to
observe autoimmunity in age-matched control mice on
a similar mixed background, disease development clearly
requires Shp1 deficiency in B cells.
How B cell-specific Shp1 deficiency lead to autoimmu-
nity is unclear. Patients with SLE, also characterized by
autoantibodies and immune-complex glomerulonephritis,
have autoreactive and polyreactive BCRs in their mature,
naive B cell repertoire. Normally, such BCRs are found in
BM B cells and recent emigrants. These data implicate
defective peripheral B cell tolerance in pathogenic anti-
body production in SLE (Yurasov et al., 2005). Conceiv-
ably, Shp1 deficiency affects peripheral tolerance, allow-
ing the persistence of autoreactive and polyreactive B
cells. Also, the B-1a cell repertoire may be altered signifi-
cantly in Shp1-deficient mice. Although Shp1-deficient B
cells are poorly responsive to anti-IgM or -CD40 stimula-
tion ex vivo, they may respond to as yet unidentified
ligands in vivo, leading to a breakdown of tolerance.
Our studies of the consequences ofPtpn6 deletion have
revealed the complexity of B cell-specific effects of Shp1
in controlling B-1a cell development and autoimmunity.
Deletion of Shp1 in additional lymphohematopoietic cell
compartments will provide a rational approach to decipher
the complex cellular and molecular mechanisms underly-
ing the inflammation and autoimmunity inmotheatenmice.
EXPERIMENTAL PROCEDURES
Gene Targeting and Mice
A targeting vector (Figure S1), containing a neor cassette flanked by
loxP sites in the 50 untranslated region of Ptpn6 exon I (II) and a loxP46 Immunity 27, 35–48, July 2007 ª2007 Elsevier Inc.site in intron 9, was constructed by standard techniques. NotI-linear-
ized targeting vector was electroporated into the 129Ola-derived ES
cell line E14.1, and G418 and gancyclovir-resistant colonies were
screened by Southern blotting with a flanking probe (Figure S1).
Homologous recombinants were transiently transfected with a cre-
encoding plasmid, and two Ptpn6f/+ clones that had excised only the
neor cassette were injected into blastocysts. The resulting chimeras
were bred to C57BL/6 mice, and germline transmission was confirmed
by Southern blotting. Ptpn6f/+ mice were intercrossed to generate
Ptpn6f/f or crossed to strains harboring CD19-cre (Rickert et al., 1997).
Mice and PCR Screening of Ptpn6 Floxed and cre Alleles
All experiments used mice on mixed C57BL/6 3 129Ola background
and, except where indicated, at 8–12 weeks of age. Floxed (550
bp), deleted (330 bp), and wild-type (350 bp) Ptpn6 alleles were
identified by PCR with primers SHCP27 (50 ACC-CTC-CAg-CTC-
CTC-TTC), SHCP29 (50 TgA-ggT-CCC-ggT-gAA-ACC), and SHCP32
(50 TgT-TAT-gCA-TgT-gTg-TAT-Cg). Wild-type (452 bp) and cre-in-
serted (715 bp) Cd19 alleles were identified by PCR with primers
CD19c (50 AAC-CAg-TCA-ACA-CCC-TTC-C), CD19d (50 CCA-gAC-
TAg-ATA-CAg-ACC-Ag) and Cre7 (50 TCA-gCT-ACA-CCA-gAg-ACg-
g). All mice used were maintained under specific pathogen-free condi-
tions according to institutional guidelines and animal-study protocols
approved by the institutional animal-care and -use committees.
Cell Preparation and Flow Cytometry
Single-cell suspensions of spleen and LN (cervical, auxillary, brachial,
and inguinal) were prepared in RPMI + 2% FCS. The same medium
was used to flush femurs and tibias and to lavage peritoneal cavities.
Erythrocytes were lysed in 0.83% NH4Cl/Tris-HCl (pH 7.2). Surface
staining was performed on 1 3 106 cells in PBS, 2% FCS, and 0.2%
azide on ice. Fluorochrome-conjugated or biotinylated B220 (RA3-
6B2), IgM (II/4.1), IgD (1.3-5), TCRb (H57597), CD45 (30F11), Ly5.1
(A20), Ly5.2 (104), AA4.1, Gr-1 (RB6-8C5), CD19 (1D3), CD5 (53-7.3),
CD23 (B3B4), CD21/35 (7G6), and CD43 (S7) monoclonal antibodies
were used. IgM, TCRb, Gr1, and AA4.1 antibodies were purchased
from eBioscience; others were purchased from BD Biosciences.
Flow-cytometric data were acquired on a FACScan, FACSCalibur, or
LSRII (BD Biosciences) and analyzed with CellQuest Pro or FlowJo
software.
Adoptive Transfer
Ly5.1+ mice (7 to 9 week old) were irradiated with 950 rad and injected
intravenously with 2 3 106 BM cells (predepleted for IgM+, CD5+, and
Ter119+ cells with biotinylated antibodies and biotin MACS) from 11- to
12-week-old Ptpn6+/+;CD19-cre or Ptpn6f/f;CD19-cre mice.
Ig Determinations
Serum IgM, IgA, IgG1, IgG2, and IgG3 from tail-vein bleeds were quan-
tified by ELISA, as described (Roes and Rajwesky, 1993). Sera were
collected prior to intraperitoneal injection of antigen on day 0 and
from immunized mice on days 7, 14, and 21. DNA antibodies were
assayed in sera from 5- to 6-month-old mice, with plasmid DNA and
boiled salmon-sperm DNA as sources of dsDNA and ssDNA,
respectively.
Proliferation Assays
CD19 MACS (Miltenyi)-purified splenic B cells were cultured with stim-
uli at 2 to 3 3 105 cells per well in RPMI, 10% FCS, 2 mM glutamine,
1 mM sodium pyruvate, and 4.9 3 105 M 2-mercaptoethanol. After
36 hr, cells were pulsed with 1 ml Ci [methyl-3H] thymidine for an addi-
tional 8 hr, and incorporation was quantified with a b-counter (Matrix
9600, Packard). B-1a cell proliferation was assessed by flow cytometry
of CD5+CD19+ cells loaded with 5 mM carboxy-fluorescein diacetate
and succinimidyl ester (CFSE, Molecular Probes) and cultured with
stimuli for 3 or 4 days.
Immunity
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Cells were loaded with 5 mM Indo-1 AM (Molecular Probes) in RPMI
and stained with B220-FITC, CD5-PE, CD4-APC, and CD8-APC anti-
bodies. After exposure to F(ab)’2 fragments of goat anti-mouse IgM
(Jackson Immunoresearch) at 37C, intracellular calcium concentra-
tions in CD5B220+ and CD5+B220lo cells were monitored for 8 min
with an LSRII.
Histopathology
Tissues fixed with Bouin’s solution or 10% formalin (Sigma) were
stained with hematoxylin and eosin (H and E) or subjected to immuno-
histochemistry (IHC). B220 (BD Biosciences) and polyclonal CD3
(Dako) antibodies were used with methods previously described (Ca-
sola et al., 2004). Transmission electron microscopy was performed
on kidney samples fixed in Karnovsky’s media. Immunofluorescence
was performed with FITC-conjugated goat antibodies against mouse
IgA, IgG, and IgM and k and l light chains (Southern Biotech).
Statistical Analysis
All analyses were performed with Prism 4 program (GraphPad Soft-
ware).
Supplemental Data
Five figures and one table are available at http://www.immunity.com/
cgi/content/full/27/1/35/DC1/.
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